Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
Year: 2019
Type: article
Source: Annals of Oncology
Institutions: Asan Medical Center, University of Ulsan, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Oregon Health & Science University, OHSU Knight Cancer Institute, University of California, Irvine, University of Colorado Anschutz, University of Miami, Sylvester Comprehensive Cancer Center, Seattle Cancer Care Alliance, University of Washington, Vall d'Hebron Institute of Oncology, University of Michigan, Michigan Medicine, Seoul National University, Seoul National University Hospital, Blueprint Medicines (United States), University of Milan, European Institute of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2990021973